Company patents

Roche Diagnostics Operations, Inc.

Roche Diagnostics Operations, Inc. surprisingly shows a strong emerging focus in Computer Security, with patent filings increasing by 150.0% year-over-year in 2026 (so far), despite its core Material & Chemical Analysis category, representing 69.1% of its portfolio, experiencing a significant decline of 18.0% in 2025 and 64.6% so far in 2026.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

447 US filings (since 2023) · 12 categories · 21 themes

Advanced Biomarker Detection Assays

Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.

Material & Chemical Analysis
Who else files here? →
236since 2023
-30.9%YoY
Integrated Molecular Diagnostic Systems

Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.

Laboratory ApparatusGenetic & Microbiological Assays
Who else files here? →
143since 2023
-29.4%YoY
Automated Liquid Handling

Systems and components designed for precise, automated manipulation, transfer, and dispensing of liquid samples and reagents, often involving pipettes, robotic arms, and specialized sample containers.

Laboratory Apparatus
Who else files here? →
114since 2023
+2.9%YoY
Physiological Monitoring & Diagnostics

Systems and methods for non-invasive or minimally invasive collection and analysis of physiological data (e.g., blood pressure, electrolytes, genetic markers, B cell repertoire) to assess patient health status, screen for conditions, or aid in diagnosis.

Healthcare Informatics
Who else files here? →
36since 2023
-41.7%YoY
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Material & Chemical AnalysisPeptides & Proteins
Who else files here? →
24since 2023
-11.1%YoY
Smart Medication Management

Systems that integrate digital technology, sensors, or connectivity to monitor, track, or automate aspects of medication administration, often providing data feedback, personalized recommendations, or secure logging.

Healthcare Informatics
Who else files here? →
21since 2023
-70.0%YoY
Molecular Biomarkers for Disease

Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.

Genetic & Microbiological Assays
Who else files here? →
20since 2023
+100.0%YoY
Ion Implantation Control & Metrology

Methods and apparatus for precise wafer positioning, ion beam uniformity, and dose monitoring during ion implantation processes in semiconductor device manufacturing.

Electron / Ion Tubes & Discharge
Who else files here? →
10since 2023
+200.0%YoY
AI for Medical Diagnostics

Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.

Healthcare InformaticsImage ProcessingComputer Vision
Who else files here? →
10since 2023
+33.3%YoY
Bioprocess Development for Proteins

Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.

Peptides & Proteins
Who else files here? →
10since 2023
+50.0%YoY
Thermal Control for Bio-Reactions

Apparatus and methods for precisely controlling temperature profiles (heating, cooling, incubation) within laboratory reaction vessels or modules to optimize biochemical processes like gene amplification or protein assays.

Laboratory Apparatus
Who else files here? →
9since 2023
+200.0%YoY
Secure Data Sharing & Rights Management

Mechanisms to facilitate the secure exchange of data between different entities or systems while enforcing usage policies, managing digital content rights, and ensuring data consistency during replication or transfer.

Computer Security
Who else files here? →
6since 2023
+100.0%YoY
Automated Visual Inspection

Systems that employ imaging and image processing to automatically detect defects, verify states, or ensure quality control in manufactured goods, printed materials, or industrial processes.

Material & Chemical Analysis
Who else files here? →
6since 2023
+100.0%YoY
Rapid Isothermal Amplification

Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.

Genetic & Microbiological Assays
Who else files here? →
6since 2023
n/a
Microfluidic Lab-on-Chip Devices

Miniaturized devices that manipulate small volumes of fluids (nanoliters to picoliters) through microchannels to perform laboratory functions like mixing, separation, reaction, and detection on a single chip.

Laboratory Apparatus
Who else files here? →
5since 2023
+100.0%YoY
Secure Data Storage & Provenance

Techniques for protecting data at rest or in backup, ensuring its integrity, confidentiality, and verifiable origin, often involving encryption, unique identifiers, or secure repositories.

Computer SecurityNetwork Security & Access Control
Who else files here? →
4since 2023
+100.0%YoY
Protein & Peptide Engineering

Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.

Peptides & Proteins
Who else files here? →
4since 2023
0.0%YoY
Immunomodulatory Protein Design

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

Peptides & Proteins
Who else files here? →
3since 2023
new
Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)
Who else files here? →
3since 2023
+100.0%YoY
Wearable Physiological Sensing

Development of devices and methods for non-invasive or minimally invasive collection and analysis of physiological data, often from wearable sensors, to monitor health, activity, or specific conditions.

Medical Diagnostics & Surgery
Who else files here? →
1since 2023
new
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
1since 2023
n/a

Patents

Showing 51-60 of 745

Page 6 of 75
US 12488971 B2GRANTED
H01J49/00

Computer implemented method for calibrating a customer mass spectrometry instrument for quantifier-qualifier-ratio check

Filed:2022-11-22Pub:2025-12-02
Applicant:Roche Diagnostics Operations, Inc.

A computer implemented method for calibrating a customer mass spectrometry instrument ( 118 ) for quantifier-qualifier-ratio check is proposed. The method comprises the following steps: a) at least one manufacturer-site standardization, wherein a set of samples of a subject and a set of calibrator samples are measured in multiple replicates on a plurality of mass spectrometry instruments ( 114 ), wherein each measurement comprises multiple reaction monitoring with quantifier and qualifier transition for analyte and internal standard, wherein at least three adjustment factors are determined from the measurements of the set of samples of a subject and the set of calibrator samples, wherein a first adjustment factor α depends on a difference between analyte and internal standard, wherein a second adjustment factor β depends on a difference between samples of a subject and calibrator samples for analyte quantifier-qualifier-ratio, wherein a third adjustment factor γ depends on a difference between samples of a subject and calibrator samples for the internal standard quantifier-qualifier-ratio; b) at least one transfer step, wherein the adjustment factors are electronically transferred to a customer mass spectrometry instrument ( 118 ); c) at least one customer-site calibration, wherein the customer-site calibration comprises at least one calibration measurement, wherein a set of calibrator samples is measured on the customer mass spectrometry instrument ( 118 ) and quantifier-qualifier-ratios are determined therefrom, wherein target values for quantifier-qualifier-ratios for analyte and for internal standard are set by applying the adjustment factors on the determined quantifier-qualifier-ratios.

US 20250364235 A1APPLICATION
H01J49/00

A METHOD FOR MULTIPLE REACTION MONITORING USING A MASS SPECTROMETRY DEVICE

Filed:2023-06-09Pub:2025-11-27
Applicant:Roche Diagnostics Operations, Inc.

A method for multiple reaction monitoring using a mass spectrometry device ( 106 ) is proposed. The method comprises the following steps: i) ( 128 ) measuring, by using the mass spectrometry device ( 106 ), multiple reaction monitoring transitions of quantifier and qualifier of both an internal standard and an analyte using staggered-multiple reaction monitoring, wherein the staggered-multiple reaction monitoring comprises at least three multiple reaction monitoring channel groups, wherein one of the multiple reaction monitoring channel groups measure at respective theoretical m/z values of the quantifier and qualifier of both the internal standard and the analyte and the two other multiple reaction monitoring channel groups measure at respective m/z values shifted to higher and lower values by a predefined level; ii) ( 130 ) comparing, for at least two groups, at least two of the quantifier/qualifier ratios of the multiple reaction monitoring transitions of the internal standard with a reference value from a database ( 126 ) by using at least one processing device ( 120 ), wherein the comparison comprises determining a deviation between the quantifier/qualifier ratios and the reference value; iii) ( 132 ) determining from the analyte and the internal standard measured multiple reaction monitoring transitions a measurement result by using the processing device ( 120 ), if the deviation for at least one of the quantifier/qualifier ratios is within at least one predefined tolerance range, otherwise rejecting ( 136 ) the measured multiple reaction monitoring transitions.

US 20250362308 A1APPLICATION
G01N33/68

TROPNIN MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION

Filed:2023-03-17Pub:2025-11-27
Applicant:Roche Diagnostics Operations, Inc.

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

US 20250355746 A1APPLICATION
G06F11/07

METHOD FOR DETECTING AND REPORTING AN OPERATION ERROR IN AN IN-VITRO DIAGNOSTIC SYSTEM AND AN IN-VITRO DIAGNOSTIC SYSTEM

Filed:2025-08-01Pub:2025-11-20
Applicant:Roche Diagnostics Operations, Inc.

The present disclosure refers to a method for detecting and reporting an operation error in an in-vitro diagnostic system ( 1 ) for determining a sample of a bodily fluid, comprising: providing a plurality of sample vessels ( 2 ) each containing a sample of a bodily fluid; and providing a plurality of functional modules ( 3 ), comprising an analysis device ( 4 ) configured to determine the sample, a handling system ( 5 ) configured to handle the plurality of sample vessels ( 2 ), and an automation track ( 6 ) provided by the handling system ( 5 ) and configured to transport the plurality of sample vessels ( 2 ) to the analysis device ( 4 ). The method further comprises: providing an operation control device ( 7 ) connected to at least one of the functional modules ( 3 ) and configured to control operation of the at least one functional module ( 3 ), and comprising one or more data processors ( 8 ), wherein an application software is running on the one or more data processors ( 8 ) for controlling operation of the at least one functional module ( 3 ); controlling operation of the at least one functional module ( 3 ) by the operation control device ( 7 ); and detecting and reporting an operation error by an error detecting and reporting device ( 9 ), comprising: detecting the operating error for the operation of at least one of the plurality of functional modules ( 3 ) and the operation control device ( 7 ), providing error data indicative of the operation error, receiving a user input through a user interface ( 10 ) after detecting the operation error, providing labelling data in response to receiving the user input, the labelling data being indicative of information related to the operating error in addition to the error data, providing error report data comprising the error data and the labelling data, and transmitting the error report data to an error repository ( 11 ) remotely located with respect to both the plurality of functional modules ( 3 ) and the operation control device ( 7 ); receiving the error report data in a machine learning process running in a data processing device connected to the error repository ( 11 ); processing the error report data by the machine learning process in the data processing device; providing a application software update for the application software in response to the processing of the error report data by the machine learning process in the data processing device; providing the application software update to the operation control device ( 7 ); and controlling operation of the at least one functional module ( 3 ) by the operation control device ( 7 ) comprising running the application software including the application software update. Further, an in-vitro diagnostic system for determining a sample of a bodily fluid is provided.

156775